mRNA pathophysiology

Clinical Trial of mRNA Universal Influenza Vaccine Candidate Begins <br> <br>https://www.niaid.nih.gov/news....-events/clinical-tri <br> <br>https://clinicaltrials.gov/ct2/show/NCT05755620 <br> <br>Clinical trial, experimental universal influenza vaccine <br> <br>National Institute of Allergy and Infectious Diseases’ (NIAID) Vaccine Research Center (VRC), <br> <br>(part of National Institutes of Health) <br> <br>Enrolling volunteers, Duke University, Durham, North Carolina <br> <br>Phase 1 trial <br> <br>H1ssF-3928 mRNA-LNP, for safety and ability to induce an immune response. <br> <br>N = up to 50 healthy volunteers, (18 through 49) <br> <br>Three groups of 10 participants each <br> <br>10, 25 and 50 micrograms <br> <br>After evaluation of the data to determine an optimum dosage, <br> <br>an additional 10 to receive the optimum dosage <br> <br>Study include a group, receive a current quadrivalent. <br> <br>Comparison between “immunogenicity and safety” <br> <br>Follow-up appointments for up to one year <br> <br>Annual seasonal flu vaccines <br> <br>Valuable tools in controlling the spread and severity of influenza <br> <br>Do not provide immunity against every flu strain. <br> <br>Each year is based on prediction <br> <br>Vaccine manufacturers then need time <br> <br>(dominant strains of the virus can change) <br> <br>An effective universal flu vaccine <br> <br>Acting NIAID Director Hugh Auchincloss <br> <br>Protecting its recipients against a wide variety of strains, <br> <br>ideally providing durable long-term immunity. <br> <br>“A universal influenza vaccine would be a major public health achievement and could eliminate the need for both annual development of seasonal influenza vaccines, as well as the need for patients to get a flu shot each year” <br> <br>Defence against the spread of a future flu pandemic. <br> <br>Both vaccines use a specific portion of a flu protein, <br> <br>Hemagglutinin (HA) stern (not head) flu protein <br> <br> <br> <br>UK cements 10-year-partnership with Moderna in major boost for vaccines and research <br> <br>https://www.gov.uk/government/....news/uk-cements-10-y <br> <br>to produce up to 250 million vaccines per year <br> <br>https://www.theguardian.com/bu....siness/2022/jun/22/m <br> <br>£1bn deal with the UK government <br> <br>UK government has committed to buying Moderna’s vaccines for the next decade. <br> <br>Harwell, Oxfordshire <br> <br>https://www.bbc.co.uk/news/uk-....england-oxfordshire- <br> <br>Innovation and Technology Centre built by the 2025 <br> <br>Moderna <br> <br>provide the UK public with access to mRNA vaccines for a wide range of respiratory diseases <br> <br>Questions <br> <br>Control of antigen dose? <br> <br>How long antigen will be produced for? <br> <br>Degree of systemic distribution? <br> <br>Degree of systemic inflammation?